Emerging targets in the AKT pathway for treatment of androgen-independent prostatic adenocarcinoma

By Graff Jeremy R  

Expert Opinion on Therapeutic Targets, Vol. 6, Iss. 1, 2002-02 ,pp. : 103-113

Informa Healthcare

Access to resources Recommend Favorite

Blockage of hERG current and the disruption of trafficking as induced by roxithromycin

By Yang Song-Hua   Zhang Yu   Duan Yan-Yan   Sun Xiao-Yan   Chen Qiu   Fan Tian-Li   Ye Zhen-Kun   Huang Chen-Zheng   Hu Xiang-Jie   Zhang Zhao   Zhang Li-Rong  

Canadian Journal of Physiology and Pharmacology, Vol. 91, Iss. 12, 2013-01 ,pp. : 1112-1118

NRC Research Press

Access to resources Recommend Favorite

Current concepts in the pharmacotherapy of benign prostatic hyperplasia

By Khastgir Jay   Arya Manit   Shergill Iqbal S   Kalsi Jas S   Minhas Sux   Mundy AnthonyR  

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 12, 2002-12 ,pp. : 1727-1737

Informa Healthcare

Access to resources Recommend Favorite

Current Adjuvant and Targeted Therapies for Pancreatic Adenocarcinoma

By  

Current Medicinal Chemistry, Vol. 15, Iss. 17, 2008-07 ,pp. : 1674-1683

Bentham Science Publishers

Access to resources Recommend Favorite

Current evidence supports the use of combination therapy in the management of benign prostatic hyperplasia

By  

Drugs & Therapy Perspectives, Vol. 28, Iss. 12, 2012-12 ,pp. : 5-8

Adis International

Access to resources Recommend Favorite